Cetuximab-IR700, a chimeric IgG1 monoclonal antibody against EGFR, was approved under certain conditions, such as limiting its use to HNSCC and was the first EGFR-targeted NIR-PIT drug to be registered for clinical use in Japan in 2020 [36]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.